Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Headache. 2008 Feb;48(2):210-20. Epub 2007 Nov 28.

Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.

Author information

  • 1The Neurology Center, Encinitas, CA 92024, USA.

Abstract

OBJECTIVE:

To compare the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc.) and divalproex sodium (DVPX; DEPAKOTE: Abbott Laboratories) as prophylaxis in reducing disability and impact associated with migraine.

BACKGROUND:

There is a need for effective, well-tolerated prophylactic treatment of migraine.

DESIGN/METHODS:

This was a randomized, double-blind, single-center prospective study. Fifty-nine patients received either BoNTA 100 U/placebo-DVPX bid or placebo-BoNTA/DVPX 250 mg bid. BoNTA/placebo injections were given at Day 0 and at Month 3. Patients were evaluated at Months 1, 3, 6, and 9.

RESULTS:

Both treatments showed significant improvements in migraine disability scores and reductions in headache days and headache index. A trend to decreased headache severity was observed with BoNTA. A greater percentage of DVPX patients reported adverse events possibly related to treatment (DVPX 75.8% vs BoNTA 50%, P = .04) and discontinued because of adverse events (DVPX 27.6% vs BoNTA 3.3%, P = .012).

CONCLUSIONS:

Both BoNTA and DVPX significantly reduced disability associated with migraine; BoNTA had a favorable tolerability profile compared with DVPX.

PMID:
18047502
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk